Licartin is developed by Eastern Hepatobiliary Surgery Hospital.

What development phase is Licartin in?

Licartin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Licartin

Eastern Hepatobiliary Surgery Hospital · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Licartin
Also known as	TACE and Licartin
Sponsor	Eastern Hepatobiliary Surgery Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma (PHASE4)
A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection (PHASE2)
A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Licartin CI brief — competitive landscape report
Licartin updates RSS · CI watch RSS
Eastern Hepatobiliary Surgery Hospital portfolio CI